0000899243-19-029824.txt : 20191220 0000899243-19-029824.hdr.sgml : 20191220 20191220185306 ACCESSION NUMBER: 0000899243-19-029824 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191112 FILED AS OF DATE: 20191220 DATE AS OF CHANGE: 20191220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DRACHMAN JONATHAN G CENTRAL INDEX KEY: 0001588467 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36327 FILM NUMBER: 191303137 MAIL ADDRESS: STREET 1: 21823 30TH DRIVE SE CITY: BOTHELL STATE: WA ZIP: 98021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Neoleukin Therapeutics, Inc. CENTRAL INDEX KEY: 0001404644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-732-2133 MAIL ADDRESS: STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS, INC DATE OF NAME CHANGE: 20140128 FORMER COMPANY: FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS (USA) INC DATE OF NAME CHANGE: 20070626 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-11-12 0 0001404644 Neoleukin Therapeutics, Inc. NLTX 0001588467 DRACHMAN JONATHAN G C/O NEOLEUKIN THERAPEUTICS, INC. 1616 EASTLAKE AVENUE E., #360 SEATTLE WA 98102 1 1 0 0 President and CEO Series A Preferred Stock 2019-11-12 4 C 0 12616 0.00 D 0 D Common Stock 2019-11-12 4 C 0 1261600 0.00 A 2079639 D Common Stock 2019-12-20 4 P 0 119047 8.40 A 2198686 D Each share of Series A Convertible Preferred Stock converted into 100 shares of the Issuer's Common Stock upon the approval of the Issuer's stockholders on November 12, 2019. Represents shares purchased in an underwritten public offering of the Issuer's Common Stock. /s/ Kamran Alam, Attorney-in-fact for Jonathan G. Drachman 2019-12-20